Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | LTK | P29376 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9332246 | 0.80 | CHEK1 (0.41) | LRRK2CHEK1AURKADAPK3JAK2 | |
| SCHEMBL5519725 | 0.76 | CSNK1A1 (0.38) | LRRK2CHEK1AURKADAPK3JAK2 | |
| SCHEMBL31674353 | 0.74 | AURKA (0.37) | LRRK2CHEK1AURKADAPK3JAK2 | |
| SCHEMBL3979877 | 0.74 | CSNK1A1 (0.37) | LRRK2CHEK1AURKADAPK3JAK2 | |
| SCHEMBL5530019 | 0.74 | MRGPRX1 (0.38) | LRRK2CHEK1AURKADAPK3JAK2 | |
| SCHEMBL3998036 | 0.74 | AURKA (0.37) | LRRK2CHEK1AURKADAPK3JAK2 | |
| SCHEMBL4947345 | 0.74 | ABL1 (0.37) | LRRK2CHEK1AURKADAPK3JAK2 | |
| SCHEMBL5521208 | 0.74 | CHEK1 (0.34) | LRRK2CHEK1AURKADAPK3JAK2 | |
| SCHEMBL2178694 | 0.73 | LRRK2 (0.46) | LRRK2CHEK1MAPK8CLK2LIMK1 | |
| SCHEMBL29367767 | 0.72 | KDR (0.42) | LRRK2KDRALDH1A1KDM4EMALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11622970-B2 | BCL-2 inhibitors and their use as pharmaceuticals | Prelude Therapeutics Incorporation (US) | 2023-04-11 | — | — | US | disclosed |
| US-20210346405-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED | 2021-11-11 | — | — | US | disclosed |
| US-20210346405-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED | 2021-11-11 | — | — | US | disclosed |
| WO-2021222174-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222174-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346405-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | BCL2, BCL2L2, BCL2L1 | LRRK2 1035/4885CHEK1 790/4885AURKA 3209/4885 |
| US-11622970-B2 | BCL-2 inhibitors and their use as pharmaceuticals | BCL2, BCL2L2, BCL2L1 | LRRK2 1035/4885CHEK1 790/4885AURKA 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.